Communiqués AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Temps réel estimé Cboe BZX 18:30:48 16/09/2026			Varia. 5j.	Varia. 1 janv.
263,73 ^USD	+0,26%		+5,15%	+15,47%

15/09	Transcript : AbbVie Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
15/09	Les prescriptions de testostérone pour les femmes augmentent, tout comme les refus et les délais	RE

Communiqués

15/09	AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum	AQ
15/09	AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign	PR
15/09	Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit	PR
10/09	AbbVie Declares Quarterly Dividend	PR
10/09	AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine	PR
03/09	AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma	PR
03/09	AbbVie Completes Acquisition of Apogee Therapeutics	PR
03/09	AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	PR
02/09	Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care	PR
01/09	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture	PR
01/09	SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings	PR
31/08	AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference	PR
27/08	AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
21/08	AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline	PR
18/08	AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support	PR
11/08	Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices	PR
05/08	UBRELVY(R) (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
04/08	Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence	PR
04/08	UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
31/07	AbbVie: Q2 Earnings Snapshot	AQ
31/07	AbbVie Reports Second-Quarter 2026 Financial Results	PR
30/07	AbbVie Announces European Commission Approval of RINVOQ for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo	AQ
30/07	AbbVie Announces European Commission Approval of RINVOQ for the Treatment of Adults and Adolescents with Severe Alopecia Areata	AQ
30/07	JUVÉDERM® Day Returns to U.S. on August 19	PR
29/07	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo	PR